Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 placebo-controlled trial of TEV-56286 in multiple system atrophy
MOH_2024-03-04_013293Phase 2Not yet recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple system atrophy (MSA) comparing ANLE138B with Placebo (2 arms). Planned start Feb 2024; status: not yet recruiting.
02
Drugs
emrusolmin
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on MOH_2024-03-04_013293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-03-04_013293.